Q3 EPS Estimates for Revolution Medicines Cut by Wedbush

Revolution Medicines, Inc. (NASDAQ:RVMD) – Equities research analysts at Wedbush lowered their Q3 2025 EPS estimates for shares of Revolution Medicines in a research report issued to clients and investors on Wednesday, August 6th. Wedbush analyst R. Driscoll now expects that the company will post earnings of $0.02 per share for the quarter, down from their prior estimate of $0.12. Wedbush has a “Outperform” rating and a $73.00 price target on the stock. The consensus estimate for Revolution Medicines’ current full-year earnings is ($3.49) per share. Wedbush also issued estimates for Revolution Medicines’ Q4 2025 earnings at ($1.33) EPS, FY2025 earnings at ($3.76) EPS, Q1 2026 earnings at ($1.37) EPS, Q2 2026 earnings at ($1.39) EPS, Q3 2026 earnings at ($1.43) EPS, Q4 2026 earnings at ($1.45) EPS, FY2026 earnings at ($5.64) EPS, FY2027 earnings at ($4.08) EPS, FY2028 earnings at ($3.51) EPS and FY2029 earnings at $1.47 EPS.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.37). Revolution Medicines’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.81) EPS.

A number of other research analysts have also commented on RVMD. Needham & Company LLC reduced their price target on shares of Revolution Medicines from $57.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, August 7th. The Goldman Sachs Group started coverage on shares of Revolution Medicines in a research report on Tuesday, July 15th. They set a “buy” rating and a $65.00 price target for the company. Oppenheimer lifted their price objective on shares of Revolution Medicines from $70.00 to $75.00 and gave the stock an “outperform” rating in a report on Thursday, May 8th. HC Wainwright reaffirmed a “buy” rating and set a $72.00 price objective (down from $73.00) on shares of Revolution Medicines in a report on Wednesday, May 14th. Finally, Guggenheim reaffirmed a “buy” rating and set a $80.00 price objective on shares of Revolution Medicines in a report on Wednesday, June 25th. Eleven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $68.82.

Revolution Medicines Stock Down 0.9%

RVMD opened at $34.70 on Monday. The company has a fifty day moving average price of $38.30 and a 200-day moving average price of $38.69. The firm has a market capitalization of $6.49 billion, a P/E ratio of -7.71 and a beta of 1.16. The company has a debt-to-equity ratio of 0.13, a current ratio of 11.79 and a quick ratio of 11.79. Revolution Medicines has a one year low of $29.17 and a one year high of $62.40.

Hedge Funds Weigh In On Revolution Medicines

Several hedge funds and other institutional investors have recently modified their holdings of RVMD. Wells Fargo & Company MN raised its stake in shares of Revolution Medicines by 51.8% during the fourth quarter. Wells Fargo & Company MN now owns 88,327 shares of the company’s stock valued at $3,863,000 after acquiring an additional 30,155 shares during the last quarter. Envestnet Asset Management Inc. raised its stake in shares of Revolution Medicines by 21.7% during the fourth quarter. Envestnet Asset Management Inc. now owns 11,425 shares of the company’s stock valued at $500,000 after acquiring an additional 2,041 shares during the last quarter. Russell Investments Group Ltd. raised its stake in shares of Revolution Medicines by 11.4% during the fourth quarter. Russell Investments Group Ltd. now owns 4,243 shares of the company’s stock valued at $186,000 after acquiring an additional 434 shares during the last quarter. Cerity Partners LLC bought a new position in shares of Revolution Medicines during the fourth quarter valued at about $250,000. Finally, Raymond James Financial Inc. bought a new position in shares of Revolution Medicines during the fourth quarter valued at about $14,067,000. 94.34% of the stock is owned by institutional investors.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.